Researchers at the University of Canberra will collaborate with a pharmaceutical company to test the efficacy of medicinal cannabis in treating melanoma.

The university announced a $1 million deal with Israel-based Cann Pharmaceutical to provide specific medical-grade strains of cannabis, which will be administered to patients along with the current standard of care for melanoma patients.

Molecular and cellular biology professor Sudha Rao said the research could benefit the almost-55,000 Australians that live with the skin cancer.

Click here to read the complete article

abc.net.au/news ~